CVE:OGN
Related posts
Nervous markets await NvidiaThis summary was created by AI, based on 2 opinions in the last 12 months.
Orogen Royalties (OGN-X) has received favorable reviews from experts, who highlight its successful approach as a small royalty generator through exploration skills. With a significant focus on acquiring royalties in exchange for innovative ideas, the company has demonstrated strong execution capabilities. The production of royalties in Mexico is reportedly performing very well, contributing to the company's growing revenue. Additionally, the Nevada silver royalty is generating substantial cash flows, which has boosted investor confidence. Experts anticipate further growth from Orogen, making it an intriguing focus for investors looking for solid opportunities in the royalty sector.
Orogen Royalties is a Canadian stock, trading under the symbol OGN-X on the TSX Venture Exchange (OGN-CV). It is usually referred to as TSXV:OGN or OGN-X
In the last year, 3 stock analysts published opinions about OGN-X. 1 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Orogen Royalties .
Orogen Royalties was recommended as a Top Pick by on . Read the latest stock experts ratings for Orogen Royalties .
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
3 stock analysts on Stockchase covered Orogen Royalties In the last year. It is a trending stock that is worth watching.
On 2025-07-02, Orogen Royalties (OGN-X) stock closed at a price of $1.97.
Selling one royalty to Triple Flag Royalties for stock. Likes it right now because company's valued at less than total value of OGN and Triple Flag combined, there's a merger arbitrage in play. The transaction is accretive to both parties. Shareholders should take the share option, rather than the cash option, and be very happy in a 2-3 year timeframe. No dividend.
(Analysts’ price target is $2.00)